

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED
MONROE, LOUISIANA**

**FINANCIAL STATEMENTS
AND INDEPENDENT AUDITOR'S REPORT
WITH SUPPLEMENTAL INFORMATION
FOR THE YEAR ENDED DECEMBER 31, 2003**

BY

**NICOLETTE SMITH RELEFORD
CERTIFIED PUBLIC ACCOUNTANT**

**113 WEST JEFFERSON AVENUE •
OFFICE 318-281-8040**

**BASTROP, LOUISIANA 71220
FAX 318-281-1726**

Under provisions of state law, this report is a public document. A copy of the report has been submitted to the entity and other appropriate public officials. The report is available for public inspection at the Baton Rouge office of the Legislative Auditor and, where appropriate, at the office of the parish clerk of court.

Release Date 9.1.04

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
 TECHNICAL RESOURCE FOUNDATION, INCORPORATED
 Monroe, Louisiana
 Financial Statements
 and Independent Auditor's Report
 with Supplemental Information
 As of and For the Year Ended December 31, 2003**

CONTENTS

	<u>STATEMENTS</u>	<u>PAGE NO.</u>
Independent Auditor's Report		1-2
Financial Statements		
Statement of Financial Position	A	4
Statement of Activities	B	5
Statement of Cash Flows	C	6
Statement of Functional Expenses	D	7
Notes to the Financial Statements		8-12
Reporting On Compliance and On Internal Control Over Financial Reporting Based On an Audit Of Financial Statements Performed In Accordance with Government Auditing Standards		13-14
Supplemental Information:		
Schedules		
Schedule of Financial Position		16
Schedule of Activities		17
Schedule of Cash Flow		18
Schedule of Functional Expenses		19
Schedule of Budget to Actual		
Genetic Disease Fund		20
United Way Fund		21
Summary Schedule of Prior Year Findings		22

Nicolette Smith Releford
Certified Public Accountant
113 West Jefferson Avenue
Bastrop, LA 71220

(318) 281-8040
releford@bayou.com



INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of
Northeast Louisiana Sickle Cell Anemia
Technical Resource Foundation, Incorporated
Monroe, Louisiana

I have audited the accompanying statement of financial position of Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated (a nonprofit organization) as of December 31, 2003, and the related statements of activities and changes in net assets, cash flows and functional expenses for the year then ended. These financial statements are the responsibility of the Organization's management. My responsibility is to express an opinion on these financial statements based on my audit.

I conducted my audit in accordance with generally accepted auditing standards and the standards applicable to the financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Those standards require that I plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. I believe that my audit provides a reasonable basis for my opinion.


In my opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated as of December 31, 2003, and the changes in its net assets and its cash flows for the year then ended in conformity with generally accepted accounting principles.

In accordance with government Auditing Standards, I have also issued my report dated June 20, 2004 on my consideration of Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated's internal control over financial reporting and my tests of its compliance with certain provisions of laws, regulations, contracts and grants.

My audit was performed for the purpose of forming an opinion on the financial statements taken as a whole. The supplemental information and schedules are presented for purposes of additional

INDEPENDENT AUDITOR'S REPORT
(Continued)

analysis and are not a required part of the basic financial statements. Such information has been subjected to the auditing procedures applied in the audit of the basic financial statements, and, in my opinion, is fairly stated in all material respects in relation to the basic financial statements taken as a whole.



Nicolette S. Releford
Certified Public Accountant

Bastrop, Louisiana
June 20, 2004

FINANCIAL STATEMENTS

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED**

Statement of Financial Position
For the Year Ended December 31, 2003

Assets	
Current Assets:	
Cash and Cash Equivalents	\$ 126,195
Total Current Assets	<u>126,195</u>
 Investments	 27,980
 Physical Properties	
Furniture and Equipment	26,161
Vehicle	16,342
Building	174,464
Accumulated Depreciation	(47,376)
Land	1,000
Total Physical Properties	<u>170,591</u>
 Total Assets	 <u><u>324,766</u></u>
 Liabilities and Net Assets	
Current Liabilities:	
Accrued Liabilities	5,628
Deferred Revenue	4,269
Total Current Liabilities	<u>9,897</u>
 Total Liabilities	 <u>9,897</u>
 Net Assets:	
Unrestricted	302,089
Temporarily Restricted	12,780
Total Net Assets	<u>314,869</u>
 Total Liabilities and Net Assets	 <u><u>324,766</u></u>

See Accompanying Auditors' Report and Notes to Financial Statements.

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED**
Statement of Activities and Changes in Net Assets
For the Year Ended December 31, 2003

Unrestricted Public Support and Revenues	
Contributions	\$ 12,300
Grants	13,750
Membership Dues	4,961
Banquet Proceeds	6,116
Other Income	3,098
Investment Income	673
Total Public Support and Revenues	<u>40,898</u>
Reclassified Net Assets	
Restrictions Satisfied by Payments	93,015
Total Reclassification Net Assets	<u>93,015</u>
Total Support and Reclassifications	<u>133,913</u>
Expenses	
Program Expenses	69,609
General & Administrative Expenses	69,280
Total Expenses	<u>138,889</u>
Change in Unrestricted Net Assets	<u>(4,976)</u>
Temporarily Restricted Public Support and Revenues	
Contribution	14,203
Grants	84,195
Net Assets Released from Restrictions	
Restrictions Satisfied by Payments	(93,015)
Change in Temporarily Net Assets	<u>5,383</u>
Change in Net Assets	<u>407</u>
Net Assets as of Beginning of Year	<u>314,462</u>
Net Assets as of End of Year	<u>\$ 314,869</u>

See Accompanying Auditors' Report and Notes to Financial Statements.

**NORTHEAST LOUISIANA SICKLE ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED**

Statement of Cash Flows
For Year Ended December 31, 2003

Operating Activities

Change in Net Assets	\$ 407
Adjustments to Reconcile Change in Net Assets to Net Cash Provided by Operating Activities:	
Depreciation	9,560
Decrease in Other Receivables	20,000
Decrease in Accrued Liabilities	(814)
Decrease in Deferred Income	(7,221)
Total Adjustments	<u>21,525</u>
Net Cash Provided by Operating Activities	<u>21,932</u>

Investing Activities

Cash Provided by Investing Activities:	
Increase in Investment Account	(260)
Cash Invested in Certificate of Deposits	(16,342)
Net Cash Provided by Investing Activities	<u>(16,602)</u>

Net Increase in Cash	<u>5,330</u>
----------------------	--------------

Cash and Cash Equivalents as of Beginning of Year	<u>120,865</u>
Cash and Cash Equivalents as of the End of Year	<u><u>\$126,195</u></u>

See Accompanying Auditors' Report and Notes to Financial Statements.

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED**
Statement of Functional Expenses
For Year Ended December 31, 2003

	General and Administrative	Program	Total
Personnel Costs			
Salaries and Wages	\$ 26,940	\$ 44,100	\$ 71,040
Payroll Taxes and Other Fringe Benefits	2,061	3,374	5,435
Total Personnel Costs	<u>29,001</u>	<u>47,474</u>	<u>76,475</u>
Other Expenses			
Advertising	225	-	225
Bank Charges	402	-	402
Conferences, Conventions, & Meetings	5,188	-	5,188
Depreciation Expense	6,292	3,268	9,560
Dues and Subscription	785	-	785
Insurance	5,289	-	5,289
Maintenance	2,621	-	2,621
Miscellaneous	694	-	694
Office Expense	5,577	-	5,577
Other Program Expense	-	3,299	3,299
Postage and Delivery	745	-	745
Printing and Publication	853	-	853
Professional/Contractual	5,477	-	5,477
Repairs	1,329	-	1,329
Supplies	-	7,122	7,122
Telephone	1,682	1,682	3,364
Travel	-	3,644	3,644
Utilities	3,120	3,120	6,240
Total Other Expenses	<u>40,279</u>	<u>22,135</u>	<u>62,414</u>
Total Functional Expenses	<u>\$ 69,280</u>	<u>\$ 69,609</u>	<u>\$ 138,889</u>

See Accompanying Auditors' Report and Notes to Financial Statements.

**Northeast Louisiana Sickle Cell Anemia Technical Resource
Foundation, Incorporated
Monroe, Louisiana**

**Notes to the Financial Statements
As of and for the Year Ended December 31, 2003**

NOTE A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations

The Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated is a private non-profit organization domiciled in the State of Louisiana at Monroe, Louisiana. The Foundation is recognized as a tax-exempt (non-profit) organization under section 501 (c) (3) of the Internal Revenue Service Code. The Foundation is supported primarily through state and private grants, contributions and donations from members, and fund-raisers. The objectives of the Foundation are primarily to provide services to persons born with sickle cell anemia, a hereditary disorder. Such services include educational program, patient assistance programs, genetic counseling, research and social services. A Board of Directors consisting of fifteen (15) members governs the Foundation. The Board Members receive no compensation.

Basis of Accounting

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with generally accepted accounting principles.

Basis of Presentation

For the period ending December 31, 2003, the Foundation followed provisions of Statement of Financial Accounting Standards No. 117, *Financial Statements of Not-for-Profit Organizations*. Statement No. 117 requires the Foundation to distinguish between contributions that increase permanently restricted net assets, temporarily restricted net assets, and unrestricted net assets. The following is a description of the three net assets categories:

Unrestricted Net Assets-Net assets that are not subject to donor-imposed stipulations.

Temporarily Restricted Net Assets-Net assets subject to donor-imposed stipulations that may or will be met either by actions of the Foundation and/or by passage of time.

Permanently Restricted Net Assets-Net assets subject to donor-imposed stipulations that they be maintained permanently by the Foundation. Generally the donors of these assets permit the Foundation to use all or part of the income earned on related investments for general or specific purposes.

Statement No. 117 also requires recognition of contributions, including contributed services meeting certain criteria, at fair values. It establishes standards for general-purpose external financial statements of not-for-profit organizations and requires a statement of financial position, a statement of activities, and a statement of cash flows.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA TECHNICAL
RESOURCE FOUNDATION, INCORPORATED
Monroe, Louisiana
Notes to the Financial Statements (Continued)

Public Support and Revenue

Revenue and public support consists mainly of fundraising, and contributions. In accordance with SFAS No. 116, "Accounting for Contributions Received and Contributions Made", contributions are recognized when the donor makes a promise to give to the Foundation that is, in substance, unconditional. Contributions that are restricted by time by the donor are reported as increases in unrestricted net assets if the restrictions expire in the fiscal year in which the contribution are recognized. All other donor-restricted contributions are reported as increases in temporarily or permanently restricted net assets depending on the nature of the restrictions. When a time restrictions expires, temporarily restricted net assets are reclassified to unrestricted net assets.

The Foundation uses the allowance method to determine uncollectible unconditional contributions receivable. The allowance is based on prior years' experience and management's analysis of specific promises made.

Depreciation

The Association follows the practice of capitalizing, at cost, all expenditures for fixed assets in excess of \$500. Depreciation is computed on a straight-line basis over the useful lives of the assets generally as follows:

Building and improvements	30 years
Furniture and equipment	7 years
Computers and accessories	5 years

The net fixed asset balance is reflected in the financial statements as a separate component in the net assets

Fair Value of Financial Instruments

The carrying amounts of cash, cash equivalents, investments, and notes payable are reported in the statement of financial position at approximate fair values because of the short maturity of those instruments.

Income Taxes

The Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated is exempt from federal income taxes under Section 501 (c) (3) of the Internal Revenue Code and therefore has made no provision for federal income taxes in the accompanying financial statements.

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires the use of management's estimates.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA TECHNICAL
RESOURCE FOUNDATION, INCORPORATED

Monroe, Louisiana

Notes to the Financial Statements (Continued)

Cash and Cash Equivalents

The Foundation considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents for purposes of the statement of cash flows exclude permanently restricted cash and cash equivalents. Under state law, the agency may deposit funds in demand accounts, interest bearing accounts, money market accounts, or time deposits with state banks organized under Louisiana law and national banks having their principal offices in Louisiana. On December 31, 2003, Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated had cash and cash equivalents totaling \$126,195 as follows:

Unrestricted	\$ 79,079
Temporarily Restricted	47,116
Total Cash	<u>\$ 126,195</u>

Total Columns

Total columns are presented to facilitate financial analysis. Data in these columns do not present financial position, results of operations and changes in net assets in conformity with generally accepted accounting principles. Neither is such data comparable to a consolidation.

NOTE B. INVESTMENTS

The investments of the Foundation consisted of two (2) certificates of deposit at December 31, 2003 in the amounts of \$10,000 and \$17,980. These certificates bear interest rates of 1.69% and 1.72%, respectively and both with automatic renewal terms and maturity every 182 days and 6 months.

NOTE C. PHYSICAL PROPERTIES

Physical Properties consisted of the following at December 31, 2003:

	Balance 12/31/2002	Additions	Deletions	Balance 12/31/2003
Furniture and Equipment	\$ 26,161	\$ -	\$ -	\$ 26,161
Vehicle	-	16,342	-	16,342
Building	174,464	-	-	174,464
Land	1,000	-	-	1,000
Less Accumulated Depreciation	(37,816)	(9,560)	-	(47,376)
	<u>\$ 163,809</u>	<u>\$ 6,782</u>	<u>\$ -</u>	<u>\$ 170,591</u>

NORTHEAST LOUISIANA SICKLE CELL ANEMIA TECHNICAL
RESOURCE FOUNDATION, INCORPORATED

Monroe, Louisiana

Notes to the Financial Statements (Continued)

NOTE D. PENSION PLAN

All employees of the Foundation are members of the Social Security System. In addition to the employees' contribution of 7.65 percent, the agency contributes an equal amount to the Social Security System. The Foundation does not guarantee the benefits granted by the Social Security System.

NOTE E. DONATED SERVICES

The value of donated services is not reflected in the accompanying financial statements since there is no objective basis available by which to measure the value of such services. However, for the purposes of this reports the amounts are immaterial.

NOTE F. COMPENSATED ABSENCES

Compensated absences are absences for which employees will be paid, such as vacation, sick leave, and sabbatical leave. The Foundation has no policy for compensated absences. Therefore, those costs are not reflected in this report. However, for the purpose of this report the amounts are considered immaterial.

NOTE G. DEFERRED REVENUE

Deferred revenue consists of the following:

Temporarily Restricted	\$ 4,269
Total	<u>\$ 4,269</u>

NOTE H. FUNCTIONAL ALLOCATION OF EXPENSES

The costs of providing the various programs and activities have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among the programs and supporting services benefited.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA TECHNICAL
RESOURCE FOUNDATION, INCORPORATED
Monroe, Louisiana
Notes to the Financial Statements (Continued)

NOTE I. FUND DESCRIPTION

For internal accounting purposes, the Organization maintains the following separate funds:

GENERAL FUND-All assets over which the Board of Directors has discretionary control have been included in the General Fund.

UNITED WAY FUND-The United Way Fund is used to account for a grant from United Way of Northeast Louisiana.

GENETIC DISEASE FUND-The Genetic Disease Fund is used to account for a state grant from the Louisiana Department of Health and Hospitals.

WALKATHON FUND-The Walkathon Fund is used to account for proceeds from an annual fundraiser.

Nicolette Smith Releford
Certified Public Accountant
113 West Jefferson Avenue
Bastrop, LA 71220

(318) 281-8040
releford@bayou.com



**REPORT ON COMPLIANCE AND ON INTERNAL CONTROL OVER
FINANCIAL REPORTING BASED ON AN AUDIT OF FINANCIAL
STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT
AUDITING STANDARDS**

To: The Board of Director's of Northeast
Louisiana Sickle Cell Anemia Resource
Foundation, Incorporated
Monroe, Louisiana

I have audited the financial statements of Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated as of and for the year ended December 31, 2003, and have issued my report thereon dated June 20, 2004. I conducted my audit in accordance with generally accepted auditing standards and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States.

Compliance

As part of obtaining reasonable assurance about whether Northeast Louisiana Sickle Cell Technical Anemia Resource Foundation, Incorporated financial statements are free of material misstatement, I performed tests of its compliance with certain provisions of laws, regulations, contracts and grants, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of my audit and, accordingly, I do not express such an opinion. The results of my tests disclosed no instances of noncompliance that are required to be reported under *Government Auditing Standards*.

Internal Control Over Financial Reporting

In planning and performing my audit, I considered Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated internal control over financial reporting in order to determine my auditing procedures for the purpose of expressing my opinion on the financial statements and not to provide assurance on the internal control over financial reporting. My consideration of the internal control over financial reporting would not necessarily disclose all matters in the internal control over financial reporting that might be material weaknesses. A material weakness is a condition in which the

**REPORT ON COMPLIANCE AND ON INTERNAL CONTROL OVER
FINANCIAL REPORTING BASED ON AN AUDIT OF FINANCIAL
STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT
AUDITING STANDARDS (Continued)**

design or operation of one or more of the internal control components does not reduce to a relatively low level the risk that misstatements in amounts that would be material in relation to the financial statements being audited may occur and not be detected within a timely period by employees in the normal course of performing their assigned functions. I noted no matters involving the internal control over financial reporting and its operation that I consider to be material weaknesses.

This report is intended solely for the information of the audit committee, management, Board of Directors, Management, and the Legislative Auditor. However, this report is a matter of public record and its distribution is not limited. Under Louisiana Revision 24:513, this report is distributed by the Legislative Auditor as a public document.



Nicolette S. Releford
Certified Public Accountant

June 20, 2004
Bastrop, Louisiana

SUPPLEMENTAL INFORMATION

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED**
Schedule of Financial Position
December 31, 2003

	Temporarily Restricted				Total All Funds
	General Fund	United Way	Genetic Disease Fund	Walkathon Fund	
Assets					
Current Assets:					
Cash and Cash Equivalents	\$ 76,079	\$ 17,094	\$ 33,022	\$ -	\$ 126,195
Due From Other Funds	27,942	-	234	15,265	43,441
Total Current Assets	<u>104,021</u>	<u>17,094</u>	<u>33,256</u>	<u>15,265</u>	<u>169,636</u>
Investments	27,980	-	-	-	27,980
Physical Properties					
Furniture and Equipment	25,516	-	645	-	26,161
Vehicles	16,342	-	-	-	16,342
Building	174,464	-	-	-	174,464
Accumulated Depreciation	(46,989)	-	(387)	-	(47,376)
Land	1,000	-	-	-	1,000
Total Physical Properties	<u>170,333</u>	<u>-</u>	<u>258</u>	<u>-</u>	<u>170,591</u>
Total Assets	<u>302,334</u>	<u>17,094</u>	<u>33,514</u>	<u>15,265</u>	<u>368,207</u>
Liabilities and Net Assets					
Current Liabilities:					
Accrued Liabilities	5,628	-	-	-	5,628
Due to Other Funds	-	14,454	28,987	-	43,441
Deferred Revenue	-	-	4,269	-	4,269
Total Current Liabilities	<u>5,628</u>	<u>14,454</u>	<u>33,256</u>	<u>-</u>	<u>53,338</u>
Net Assets:					
Unrestricted	296,706	2,640	258	15,265	314,869
Total Net Assets	<u>296,706</u>	<u>2,640</u>	<u>258</u>	<u>15,265</u>	<u>314,869</u>
Total Liabilities and Net Assets	<u>\$ 302,334</u>	<u>\$ 17,094</u>	<u>\$ 33,514</u>	<u>\$ 15,265</u>	<u>\$ 368,207</u>

See Accompanying Auditors' Report and Notes to Financial Statements.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED
Schedule of Activities
And Changes in Net Assets
December 31, 2003

	Unrestricted	Temporarily Restricted			Total All Funds
	General Fund	United Way	Genetic Disease Fund	Walkathon Fund	
Unrestricted Public Support and Revenues					
Contributions	\$ 12,300	\$ -	\$ -	\$ -	\$ 12,300
Grants	13,750	-	-	-	13,750
Membership Dues	4,961	-	-	-	4,961
Banquet Proceeds	6,116	-	-	-	6,116
Other Income	3,098	-	-	-	3,098
Investment Income	673	-	-	-	673
Total Unrestricted Public Support and Revenues	40,898	-	-	-	40,898
Reclassified Net Assets					
Restrictions Satisfied by Payments	93,015	-	-	-	93,015
Total Reclassification Net Assets	93,015	-	-	-	93,015
Total Support and Reclassifications	133,913	-	-	-	133,913
Expenses					
Program Expenses	69,609	-	-	-	69,609
General & Administrative Expenses	69,280	-	-	-	69,280
Total Expenses	138,889	-	-	-	138,889
Change in Unrestricted Net Assets	(4,976)	-	-	-	(4,976)
Temporarily Restricted Public Support and Revenues					
Contribution	-	-	-	14,203	14,203
Grants	-	27,475	56,720	-	84,195
Net Assets Released from Restrictions	-	-	-	-	-
Restrictions Satisfied by Payments	-	(27,475)	(56,849)	(8,691)	(93,015)
Change in Temporarily Restricted Net Assets	-	-	(129)	5,512	5,383
Change in Net Assets	(4,976)	-	(129)	5,512	407
Net Assets as of Beginning of Year	301,682	2,640	387	9,753	314,462
Net Assets as of End of Year	\$ 296,706	\$ 2,640	\$ 258	\$ 15,265	\$ 314,869

See Accompanying Auditors' Report and Notes to Financial Statements.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED
Schedule of Cash Flows
December 31, 2003

	Unrestricted	Temporarily Restricted			Total All Funds
	General Fund	United Way	Genetic Disease Fund	Walkathon Fund	
Operating Activities					
Change in Net Assets	\$ (4,976)	\$ -	\$ (129)	\$ 5,512	\$ 407
Adjustments to Reconcile Change in Net Assets to Net Cash Provided by Operating Activities:					
Depreciation	9,431	-	129	-	9,560
Decrease (Increase) in Due from Other Funds	(14,416)	-	-	(5,512)	(19,928)
(Increase) Decrease in Other Receivables	20,000	-	-	-	20,000
Increase (Decrease) in Accrued Liabilities	(814)	-	-	-	(814)
Increase (Decrease) in Due to Other Funds	-	7,623	12,305	-	19,928
Increase (Decrease) in Deferred Income	-	-	(7,221)	-	(7,221)
Total Adjustments	<u>14,201</u>	<u>7,623</u>	<u>5,213</u>	<u>(5,512)</u>	<u>21,525</u>
Net Cash Provided by Operating Activities	<u>9,225</u>	<u>7,623</u>	<u>5,084</u>	<u>-</u>	<u>21,932</u>
Investing Activities					
Cash Provided by Investing Activities:					
Increase in Investment Account	(260)	-	-	-	(260)
Cash Paid For Vehicle	(16,342)	-	-	-	(16,342)
Net Cash Provided (Used) by Investing Activities	<u>(16,602)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(16,602)</u>
 Net Increase (Decrease) in Cash	 <u>(7,377)</u>	 <u>7,623</u>	 <u>5,084</u>	 <u>-</u>	 <u>5,330</u>
Cash and Cash Equivalents as of Beginning of Year	83,456	9,471	27,938	-	120,865
Cash and Cash Equivalents as of the End of Year	<u>\$ 76,079</u>	<u>\$ 17,094</u>	<u>\$ 33,022</u>	<u>\$ -</u>	<u>\$ 126,195</u>

See Accompanying Auditors' Report and Notes to Financial Statements.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED
Schedule of Functional Expenses

	Temporarily Restricted Net Assets Released From Restrictions				Total All Funds
	General Fund	United Way Fund	Genetic Disease Fund	Walkathon Fund	
Program Expenses					
Personnel Costs					
Salaries and Wages	\$ 2,750	\$ 23,850	\$ 17,500	\$ -	\$ 44,100
Payroll Taxes and Other Fringe Benefits	410	1,625	1,339	-	3,374
Total Personnel Costs	<u>3,160</u>	<u>25,475</u>	<u>18,839</u>	<u>-</u>	<u>47,474</u>
Other Expenses					
Depreciation	3,268	-	-	-	3,268
Other Program Expense	3,215	84	-	-	3,299
Specific Assistance to Individuals	-	-	-	-	-
Supplies	-	100	1,808	5,214	7,122
Telephone	624	309	749	-	1,682
Travel	-	-	167	3,477	3,644
Utilities	667	-	2,453	-	3,120
Total Other Expenses	<u>7,774</u>	<u>493</u>	<u>5,177</u>	<u>8,691</u>	<u>22,135</u>
Total Program Expenses	<u>10,934</u>	<u>25,968</u>	<u>24,016</u>	<u>8,691</u>	<u>69,609</u>
General & Administrative Expenses					
Personnel Costs					
Salaries and Wages	1,120	-	25,820	-	26,940
Payroll Taxes and Other Fringe Benefits	86	-	1,975	-	2,061
Total Personnel Costs	<u>1,206</u>	<u>-</u>	<u>27,795</u>	<u>-</u>	<u>29,001</u>
Other Expenses					
Advertising	225	-	-	-	225
Bank Charges	402	-	-	-	402
Conferences, Conventions, & Meetings	5,188	-	-	-	5,188
Depreciation Expense	6,163	-	129	-	6,292
Dues and Subscription	785	-	-	-	785
Insurance	5,186	103	-	-	5,289
Maintenance	2,621	-	-	-	2,621
Miscellaneous	573	-	121	-	694
Office Expense	3,821	170	1,586	-	5,577
Postage and Delivery	645	100	-	-	745
Printing and Publication	844	9	-	-	853
Professional/Contractual	4,977	500	-	-	5,477
Repairs	1,329	-	-	-	1,329
Supplies	-	-	-	-	-
Telephone	308	625	749	-	1,682
Travel	-	-	-	-	-
Utilities	667	-	2,453	-	3,120
Total Other Expenses	<u>33,734</u>	<u>1,507</u>	<u>5,038</u>	<u>-</u>	<u>40,279</u>
Total General & Administrative Expenses	<u>34,940</u>	<u>1,507</u>	<u>32,833</u>	<u>-</u>	<u>69,280</u>
Total Functional Expenses	<u>\$ 45,874</u>	<u>\$ 27,475</u>	<u>\$ 56,849</u>	<u>\$ 8,691</u>	<u>\$ 138,889</u>

See Accompanying Auditors' Report and Notes to Financial Statements.

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED**
Genetic Disease Fund
Budget to Actual
December 31, 2003

	<u>Budgeted</u>	<u>Actual</u>	<u>Variance</u>
Revenue			
Grants	56,858	56,720	138
Total Revenue	<u>56,858</u>	<u>56,720</u>	<u>138</u>
Personnel Costs			
Salaries and Wages	44,596	43,320	1,276
Payroll Taxes and Other Fringe Benefits	3,902	3,314	588
Total Personnel Costs	<u>48,498</u>	<u>46,634</u>	<u>1,864</u>
Other Expenses			
Personnel Travel	-	2,453	(2,453)
Operating Services	6,849	5,954	895
Operating Supplies	1,150	1,808	(658)
Total Other Expenses	<u>7,999</u>	<u>10,215</u>	<u>(2,216)</u>
Total Expenses	<u>56,497</u>	<u>56,849</u>	<u>(352)</u>
Change in Net Assets	<u>361</u>	<u>(129)</u>	<u>490</u>

See Accompanying Auditors' Report and Notes to Financial Statements.

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED**
United Way Fund
Budget to Actual
December 31, 2003

	<u>Budgeted</u>	<u>Actual</u>	<u>Variance</u>
Revenue			
Grants	27,475	27,475	-
Total Revenue	27,475	27,475	-
Personnel Costs			
Salaries and Wages	23,000	23,850	(850)
Payroll Taxes and Other Fringe Benefits	1,625	1,625	-
Total Personnel Costs	<u>24,625</u>	<u>25,475</u>	<u>(850)</u>
Other Expenses	<u>2,850</u>	<u>2,000</u>	<u>850</u>
Total Expenses	<u>27,475</u>	<u>27,475</u>	<u>-</u>
Change in Net Assets	<u>-</u>	<u>-</u>	<u>-</u>

See Accompanying Auditors' Report and Notes to Financial Statements.

**Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Inc.
Summary Schedule of Prior Year Findings
December 31, 2003**

Finding: 02-01

Related Party Transaction:

The organization does not have a policy restricting related party transaction. In December of 2001, the Foundation sold a building for \$23,000. The Treasurer of the organization represented the Foundation as the attorney for the sale. The attorney released a check to the former President, (now deceased), for the net sale proceeds of \$20,000 which was less the selling expenses of \$3,000. The check had not been deposited in the account of the Foundation as of December 31, 2002. According to the attorney, the check also had not cleared his bank account as of December 31, 2002 a replacement check was not issued by December 31, 2002.

Status:

CLEARED